Guidelines/Evidence-based calculators and algorithms for better cardiac care.

Fill the calculators from a report or photo

Age, weight, height, BP, pulse, labs in any unit and echo measurements (LV dimensions, EF, peak and mean gradients…), English or Arabic. No names are kept: each patient gets a medical number.

Favourite

Your tools, kept on this device only.

No favourites yet. Press “Add to ⭐” beside the name of any tool to keep it here.

Basic calculations

BMI with body surface area, kidney function, lab unit and temperature conversion, pulse (postural tachycardia, bradycardia and tachycardia) and blood pressure (hypertension grades, inter-limb BP difference, BP difference positional and on breathing: orthostatic hypotension, supine hypertension, pulsus paradoxus)

BMI & BSA — body mass index and body surface area

Height in cm or ft + in, weight in kg or lb → WHO class and BSA by four formulas

decision tool · 7 refs

eGFR — CKD-EPI 2021 & Cockcroft-Gault

Race-free CKD-EPI eGFR with KDIGO stage, plus creatinine clearance for drug dosing

decision tool · 3 refs

Lab unit conversion — mg/dL ↔ µmol/L and mmol/L

Common labs both ways: lipids, diabetes, renal, liver, haematology and cardiac markers

decision tool · 3 refs

Temperature conversion — °C ↔ °F

Celsius to Fahrenheit and back, with the core temperature band

decision tool · 4 refs

Pulse

Postural tachycardia: pulse on standing (POTS)

Supine and standing heart rate and BP → orthostatic tachycardia (rise ≥ 30 bpm, ≥ 40 at age 12–19), POTS criteria or orthostatic hypotension

decision tool · 4 refs

Bradycardia with a pulse

Adverse features and risk of asystole → atropine, chronotropic infusion, transcutaneous or transvenous pacing, and drug-specific antidotes

decision tool · 3 refs

Tachycardia with a pulse

Stable or unstable, narrow or broad, regular or irregular → synchronised cardioversion energy, vagal manoeuvres, adenosine, rate control or antiarrhythmics

decision tool · 5 refs

Blood pressure

Hypertension grades: ESC 2024 and ACC/AHA 2025

Office, home or ambulatory BP → ESC non-elevated / elevated / hypertension, ESH grade 1–3 and ACC/AHA stage, with treatment and targets

decision tool · 4 refs

Inter-Limb BP difference

Both arms and both legs → inter-arm difference (subclavian stenosis, aortic dissection), coarctation, Hill's sign of AR and the ankle-brachial index

decision tool · 8 refs

BP difference: positional and on breathing

Supine and standing BP → orthostatic hypotension (classical or delayed, neurogenic ΔHR/ΔSBP < 0.5) and supine hypertension; SBP in expiration and inspiration → pulsus paradoxus (≥ 10 mmHg) and tamponade

decision tool · 9 refs

Cardiac arrest: adult ACLS

Adult cardiac arrest with a CPR cycle timer, reversible causes and post-ROSC care

Adult cardiac arrest: CPR and ACLS with code timer

Shockable or non-shockable rhythm → shocks, epinephrine and amiodarone timing, 2-minute CPR cycle timer, event log and the 4 Hs and 4 Ts

decision tool · 7 refs

Post-cardiac arrest care after ROSC

ECG, shock and coma → coronary angiography timing, oxygen, CO₂ and blood pressure targets, target temperature and how to reach it, prognostication and the post-arrest care team

decision tool · 10 refs

Hypertensive emergencies

Emergency vs urgency (asymptomatic severe hypertension) triage, condition-specific targets and drugs, IV dosing and aftercare, and acute neurological BP targets for stroke, ICH and SAH

Hypertensive emergency vs urgency (= asymptomatic severe hypertension)

Hypertensive emergency vs urgency (asymptomatic severe)

Severe BP + acute organ-damage checklist (fundi, troponin, kidneys, TMA, CXR, echo) → emergency (IV, ICU) or urgency = asymptomatic severe hypertension (oral, outpatient)

decision tool · 10 refs

Hypertensive emergency targets and drugs

Aortic dissection, ACS, pulmonary oedema, malignant HTN, encephalopathy, catecholamine crisis, pre-eclampsia → timeframe, target, first-line drug and what to avoid

decision tool · 14 refs

IV antihypertensive dosing

Weight-based bolus and infusion rates with pump mL/h: labetalol, nitroglycerin, nitroprusside, nicardipine, clevidipine, esmolol, urapidil, phentolamine, hydralazine, enalaprilat

decision tool · 8 refs

Transition and aftercare

IV-to-oral switch, discharge regimen, follow-up timing and a secondary hypertension screen (young, resistant, hypokalaemia, flash pulmonary oedema)

decision tool · 9 refs

Neurological emergencies

Acute neurological BP targets

Ischaemic stroke (no reperfusion, thrombolysis, thrombectomy), ICH and aneurysmal SAH → BP threshold and target, AHA/ASA beside ESC

decision tool · 10 refs

ECG

LVH voltage with bundle branch block, QTc, Sgarbossa, STEMI equivalents and wide complex tachycardia

ECG LVH voltage criteria & Romhilt-Estes

Sokolow-Lyon, Cornell, Peguero-Lo Presti, Romhilt-Estes points — adjusted for RBBB, LBBB and LAFB

decision tool · 7 refs

QTc — corrected QT interval

Bazett, Fridericia, Framingham and Hodges, with wide-QRS adjustment and drug monitoring

decision tool · 4 refs

Sgarbossa, Smith-modified & Barcelona

Acute occlusion MI in LBBB or ventricular paced rhythm

decision tool · 4 refs

STEMI criteria & STEMI equivalents

Sex- and age-specific ST-elevation thresholds plus posterior, De Winter, Wellens, aVR and other STEMI-equivalent patterns

decision tool · 7 refs

Wide complex tachycardia: VT vs SVT

Brugada, aVR (Vereckei) and lead II criteria, flutter with aberrancy, and acute management

decision tool · 8 refs

Prevention

10-year cardiovascular risk, risk enhancers and modifiers, LDL-C targets, coronary calcium, and statin / aspirin / BP decisions

AHA PREVENT™

10-year ASCVD risk (plus total CVD and HF) with CAC guidance (age 30–79)

decision tool · 3 refs

ASCVD Risk (Pooled Cohort Equations)

10-year hard ASCVD risk and statin decision (age 40–79)

decision tool · 3 refs

ESC SCORE2

10-year fatal + non-fatal CVD by European risk region (age 40–69)

decision tool · 2 refs

ESC SCORE2-OP

10-year fatal + non-fatal CVD in older people by European risk region (age ≥ 70)

decision tool · 2 refs

Modified Framingham (Canada)

10-year CVD risk, doubled for premature family history, with CCS statin indications (age 40–75)

decision tool · 3 refs

QRISK3 (UK)

10-year CHD, stroke or TIA risk and the NICE 10% statin threshold (age 25–84; ≥ 85 → atorvastatin 20 mg)

decision tool · 3 refs

AusCVD Risk (Australia)

5-year CVD risk category, clinically high-risk conditions and reclassification factors (age 45–79)

decision tool · 3 refs

PREDICT (New Zealand)

5-year CVD risk with the NZ 2018 treatment thresholds; diabetes-specific equation (age 30–79)

decision tool · 3 refs

Risk enhancers and modifiers

Lp(a), apoB, hs-CRP, autoimmune disease, family history, carotid/femoral Doppler, ABI and CAC → statin decision (ESC vs ACC/AHA 2026)

decision tool · 7 refs

LDL-C targets

LDL-C, non-HDL-C and apoB goals for CAD, PCI, CABG, stroke, PAD, CKD, FH, type 1 and type 2 diabetes and high risk (ESC vs ACC/AHA 2026)

decision tool · 6 refs

LDL-C — Martin/Hopkins equation

More accurate calculated LDL-C than Friedewald, with ESC goals

decision tool · 4 refs

Coronary artery calcium (CAC) score

Agatston score → CAC-DRS, statin and LDL-C goals (ACC/AHA and ESC), MESA-based aspirin guidance, high-risk features when CAC < 100

decision tool · 9 refs

Coronary artery disease

Chest pain pathway from the ER to the next test, ACS risk, heart failure class and revascularisation strategy

Chest pain pathway: from ER, ECG and troponin to the next test

ECG, hs-cTn 0h/1h, risk features and clinical likelihood → primary PCI, invasive timing, or TMT / CCTA / nuclear / stress echo / CMR / angiography

decision tool · 6 refs

TIMI Risk Score — UA/NSTEMI

14-day death, MI or urgent revascularisation in NSTE-ACS

7 items · point score · 2 refs

TIMI Risk Score — STEMI

30-day mortality in STEMI eligible for reperfusion

8 items · point score · 2 refs

GRACE Score — In-hospital mortality

Admission risk in ACS; drives timing of invasive strategy

8 items · point score · 2 refs

Killip Classification

Bedside heart-failure class in acute MI

1 items · point score · 2 refs

HEART Score

Chest pain in the ED — 6-week MACE

5 items · point score · 2 refs

CABG vs PCI — Heart Team guide

Revascularisation mode by anatomy, SYNTAX and diabetes

decision tool · 4 refs

Interventions

Cath-lab and structural decisions: complexity, bifurcation and CTO, kidneys, bleeding, DAPT, physiology, TAVI suitability and mitral TEER

SYNTAX score

Lesion-by-lesion anatomical complexity for CABG vs PCI

decision tool · 4 refs

SYNTAX Score II

4-year mortality with PCI vs CABG from anatomy plus clinical factors

decision tool · 4 refs

Bifurcation strategy (Medina + DEFINITION)

Provisional vs planned two-stent technique

decision tool · 5 refs

J-CTO Score

Difficulty of guidewire crossing in CTO PCI

5 items · point score · 2 refs

PROGRESS-CTO Score

Technical success of CTO PCI

4 items · point score · 1 refs

Mehran Score — Contrast-induced nephropathy

CIN and dialysis risk after PCI

8 items · point score · 2 refs

ARC-HBR Criteria

High bleeding risk definition for PCI

15 items · point score · 2 refs

DAPT Score

Should DAPT continue beyond 12 months after PCI?

9 items · point score · 2 refs

Intracoronary physiology & IVUS

FFR, iFR, RFR, QFR and IVUS MLA thresholds

decision tool · 4 refs

Maximum contrast dose

MACD and contrast/eGFR ceilings before PCI

decision tool · 2 refs

CRUSADE Bleeding Score

In-hospital major bleeding in NSTEMI

8 items · point score · 2 refs

OCT Calcium Score

Predicts stent underexpansion → plaque modification

3 items · point score · 2 refs

IVUS Calcium Score

IVUS predictors of stent underexpansion

4 items · point score · 2 refs

SCAI Shock Stages

Cardiogenic shock staging and MCS escalation

2 items · point score · 4 refs

Stent thrombosis (ARC definitions)

Definite / probable / possible and timing

decision tool · 2 refs

TAVI suitability — Heart Team guide

AS severity, age, EuroSCORE II, frailty and CT anatomy → TAVI vs SAVR

decision tool · 9 refs

Mitral TEER: indications and echo suitability

MR mechanism and severity, COAPT criteria, Heart Team factors and TOE anatomy → TEER, surgery or advanced HF therapy

decision tool · 9 refs

Rheumatic & infective

Rheumatic fever and infective endocarditis

Revised Jones Criteria

Acute rheumatic fever diagnosis & secondary prophylaxis

decision tool · 2 refs

Duke Criteria — Infective endocarditis

Definite / possible / rejected IE and surgical triggers

decision tool · 3 refs

Echocardiography & valvular

LV systolic and diastolic function, LV mass, valve grading and intervention, Wilkins score for valvotomy, prosthetic valves, right heart and IVC

LV systolic function — grade

LVEF ≥ 50% normal in men and women; biplane volumes, FS, GLS, WMSI → mild / moderate / severe

decision tool · 5 refs

LV diastolic function — echo grading

E/A, e′, E/e′, TR velocity, LAVI → grade I–III

decision tool · 2 refs

LV hypertrophy — mass & geometry

LV mass index and RWT → concentric remodelling, concentric or eccentric LVH

decision tool · 4 refs

Aortic stenosis — echo grading

Vmax, gradient, AVA, optional DVI, CT valve calcium and dobutamine stress echo

decision tool · 5 refs

Aortic regurgitation — echo grading

VC, PHT, EROA, RVol, RF and LV triggers

decision tool · 3 refs

Mitral regurgitation — echo grading

Primary vs secondary MR, surgery and TEER triggers

decision tool · 3 refs

Mitral stenosis — echo grading

MVA, PHT, gradient, PASP and PMBC suitability

decision tool · 3 refs

Wilkins Score

Mitral valve suitability for balloon valvotomy

4 items · point score · 2 refs

Prosthetic valve assessment

Doppler obstruction criteria, patient–prosthesis mismatch, INR targets and thrombosis management

decision tool · 6 refs

Right ventricle, IVC & PH probability

RV dilatation grade, TAPSE and FAC grades of RV dysfunction, RA pressure, PASP

decision tool · 4 refs

IVC — collapsibility & RA pressure

IVC diameter + collapsibility index → expected RA pressure (3 / 8 / 15 mmHg)

decision tool · 3 refs

Atrial fibrillation

Stroke and bleeding risk, DOAC choice in CKD and liver disease, and stopping before surgery

CHA₂DS₂-VASc / CHA₂DS₂-VA

Stroke risk and anticoagulation decision in AF

7 items · point score · 3 refs

HAS-BLED

Major bleeding risk on anticoagulation

9 items · point score · 2 refs

DOAC choice & dose — CKD and liver disease

Apixaban, edoxaban, rivaroxaban and dabigatran doses by CrCl, Child-Pugh, age, weight and interactions

decision tool · 7 refs

Stopping DOACs and warfarin before surgery

Last-dose timing by drug, CrCl and procedural bleeding risk; bridging and restart

decision tool · 5 refs

Heart failure

Stages A–D and prevention, HFrEF (LVEF < 50%) drug therapy with IV iron, ivabradine and digoxin indications, HFpEF diagnosis and treatment, and devices: ICD, CRT-P and CRT-D

Stages of heart failure (A–D) and prevention

Risk factors, structural disease, biomarkers and symptoms → stage A, B, C or D with prevention and management steps

decision tool · 2 refs

HFrEF (LVEF < 50%): foundational and additional therapy

LVEF, NYHA, BP, HR, K⁺, eGFR, iron studies and current drugs → the four FMT classes, an ESC 2026 indication check for IV iron, ivabradine and digoxin/digitoxin with doses, other additional therapy, devices and stage D referral

decision tool · 9 refs

HFpEF: diagnosis (H2FPEF, HFA-PEFF) and treatment

Natriuretic peptide, echo and clinical data → H2FPEF and HFA-PEFF scores, ESC criteria, then SGLT2i and comorbidity treatment

decision tool · 7 refs

Devices: ICD and CRT

CRT and CRT-D: cardiac resynchronisation

LVEF, FMT, QRS duration and morphology, rhythm and ICD indication → CRT class, then CRT-P or CRT-D

decision tool · 7 refs

ICD / CRT-D indications

ICD, CRT-P or CRT-D — guided by LVEF, QRS and NYHA

decision tool · 5 refs

Cardiomyopathy

Sudden cardiac death risk in HCM

HCM Risk-SCD

5-year sudden cardiac death risk and ICD decision

decision tool · 3 refs

DVT & prophylaxis

DVT diagnosis, and VTE and bleeding risk for medical and surgical thromboprophylaxis

DVT diagnosis

Wells Score — DVT

Pre-test probability of deep vein thrombosis

10 items · point score · 2 refs

Medical prophylaxis

Padua Prediction Score

VTE prophylaxis in hospitalised medical patients

11 items · point score · 2 refs

IMPROVE VTE Score

VTE risk in hospitalised medical patients (with the IMPROVEDD D-dimer option); pair with IMPROVE bleeding

8 items · point score · 4 refs

IMPROVE Bleeding Score

In-hospital bleeding risk in medical patients: ≥ 7 → mechanical rather than drug prophylaxis

11 items · point score · 3 refs

Surgical prophylaxis

Caprini Score

VTE risk and prophylaxis in surgical patients

23 items · point score · 13 refs

Pulmonary embolism

Diagnosis with adjusted D-dimer strategies, prognosis and home treatment, bleeding on anticoagulation, treatment duration and cancer-associated VTE

PE diagnosis

PE diagnostic & treatment pathway

Interactive ESC 2019 and ACC/AHA 2026 flow chart from suspicion to treatment

decision tool · 3 refs

Wells Score — PE

Clinical probability of pulmonary embolism

7 items · point score · 2 refs

Revised Geneva Score

Fully objective PE clinical probability

8 items · point score · 2 refs

Simplified Geneva Score

Revised Geneva with 1 point per item: three-level or two-level (PE unlikely / likely)

8 items · point score · 3 refs

PERC Rule

Rule out PE without testing in low-risk patients

8 items · point score · 2 refs

YEARS algorithm

3 items set the D-dimer threshold: none → < 1000 µg/L excludes PE, any → < 500 µg/L; pregnancy-adapted

decision tool · 3 refs

Age-adjusted D-dimer

Cut-off = age × 10 µg/L over 50 years in patients with non-high clinical probability

decision tool · 2 refs

PEGeD

D-dimer adjusted to Wells pre-test probability: low → < 1000, moderate → < 500, high → imaging

decision tool · 2 refs

4PEPS

4-level PE clinical probability with a matching D-dimer strategy: no test, < 1000, age-adjusted or imaging

12 items · point score · 2 refs

PE prognosis & management

ESC PE risk class

High, intermediate-high, intermediate-low or low from haemodynamics, sPESI/PESI, RV imaging and troponin

decision tool · 4 refs

PESI (original)

11 weighted items including age → 5 classes of 30-day mortality

decision tool · 3 refs

Simplified PESI (sPESI)

30-day mortality in confirmed PE

6 items · point score · 2 refs

Hestia Criteria

Eligibility for outpatient (home) treatment of acute PE: any criterion → treat in hospital

11 items · point score · 4 refs

Bova Score

PE-related complications in normotensive PE

4 items · point score · 2 refs

FAST Score

H-FABP (or hs-troponin T), Syncope, Tachycardia: complicated course in normotensive PE

3 items · point score · 3 refs

PE obstruction index

Qanadli (CT-PA) and Miller (catheter angiography) clot burden; ≥ 40% Qanadli → high risk of RV strain

decision tool · 5 refs

Bleeding risk on anticoagulation

VTE-BLEED

Major bleeding risk during stable anticoagulation for VTE (beyond the first 30 days)

6 items · point score · 3 refs

RIETE Bleeding Score

Major bleeding in the first 3 months of anticoagulation for VTE

6 items · point score · 2 refs

Anticoagulation duration & recurrence

HERDOO2

Can a woman with a first unprovoked VTE stop anticoagulation after 5–12 months?

4 items · point score · 3 refs

DASH Score

Recurrence risk after stopping anticoagulation for a first unprovoked VTE

4 items · point score · 2 refs

Vienna prediction model

Sex, VTE location and D-dimer after stopping → recurrence risk after a first unprovoked VTE

decision tool · 5 refs

Cancer-associated VTE

Khorana Score

VTE risk in ambulatory cancer patients starting chemotherapy: primary thromboprophylaxis

5 items · point score · 5 refs

Ottawa Score

Recurrence risk in the first 6 months of anticoagulation for cancer-associated VTE

4 items · point score · 3 refs

Medical

Diabetes and chronic kidney disease: cardiovascular risk and cardiorenal protection

Diabetes: cardiovascular risk and cardioprotective therapy

ASCVD, HF, kidney damage or SCORE2-Diabetes → ESC risk category, SGLT2i / GLP-1 RA / finerenone, LDL-C, BP and HbA1c goals

decision tool · 8 refs

Chronic kidney disease: cardiovascular risk and cardiorenal therapy

eGFR + UACR → KDIGO G/A stage and heat map, ESC 2026 risk category, statin, RAS inhibitor + SGLT2i, finerenone, semaglutide and BP targets

decision tool · 11 refs

Surgical: preoperative assessment

Cardiac risk before non-cardiac surgery: RCRI, functional capacity and the ESC pathway, then VTE prophylaxis with the Caprini score

Preoperative cardiac assessment — ESC pathway

Surgical and patient risk → ECG, troponin, BNP, echo, stress imaging, timing and medications

decision tool · 3 refs

RCRI — Revised Cardiac Risk Index (Lee)

Six-item index of major cardiac complications after non-cardiac surgery

6 items · point score · 3 refs

DASI — Duke Activity Status Index

Functional capacity in METs from 12 questions

decision tool · 3 refs

VTE prophylaxis

Caprini Score

VTE risk and prophylaxis in surgical patients

23 items · point score · 13 refs

Cardiovascular disease in pregnancy

Maternal risk by mWHO 2.0 class (ESC 2025) and CARPREG II; hypertension and pre-eclampsia: diagnosis, delivery, emergency drugs and magnesium sulphate

Heart disease in pregnancy

mWHO 2.0 — maternal cardiovascular risk

Class I to IV (ESC 2025) with event rates, Pregnancy Heart Team involvement, counselling, care and place of delivery

decision tool · 3 refs

CARPREG II

Risk of maternal cardiac events in pregnancy with heart disease

10 items · point score · 2 refs

Hypertension and pre-eclampsia

Hypertension in pregnancy and pre-eclampsia: algorithm

Chronic vs gestational hypertension, pre-eclampsia with or without severe features, HELLP and eclampsia → BP targets, magnesium and timing of delivery

decision tool · 10 refs

Antihypertensives and magnesium sulphate in pregnancy

Methyldopa (Aldomet), labetalol, nifedipine; emergency IV labetalol, hydralazine and oral nifedipine step by step; MgSO₄ regimens and pump rate

decision tool · 9 refs

Coming soon

New sections and cath-lab tools

Cardio-oncology

Baseline risk before cardiotoxic cancer therapy (HFA-ICOS), surveillance for cancer therapy–related cardiac dysfunction, and troponin- and GLS-based decisions.

Pulmonary hypertension

ESC/ERS 2022 haemodynamic definitions and clinical groups, risk stratification (COMPERA, REVEAL Lite 2) and the treatment algorithm for PAH.

Paediatric and congenital heart disease

Shunt quantification (Qp:Qs), adult congenital heart disease follow-up, and timing of intervention for ASD, VSD, PDA, coarctation and tetralogy of Fallot.

PRECISE-DAPT

Five-item bleeding score (age, CrCl, Hb, WBC, prior bleeding) to choose short vs standard DAPT.

Left main PCI optimisation

IVUS MSA targets per segment (5-6-7-8 rule) and post-PCI checklist.

Access-site planner

Radial vs femoral selection, large-bore access closure and limb ischaemia checks for MCS.